Robert Langreth

Robert Langreth is a financial journalist at Bloomberg, reporting on the latest news and developments in the finance industry. His work primarily focuses on pharmaceutical companies and their innovations, as well as cyberattacks affecting businesses in the United States. He has covered Gilead Sciences' experimental HIV prevention shot, which showed 100% effectiveness in preventing HIV cases in African women during a major trial. Langreth also reports on topics such as car dealerships, NATO-Russia relations, and hedge fund talent schools. Prior to joining Bloomberg, Langreth worked at various financial news outlets, honing his skills in reporting on the finance industry.

Biography:  https://finance.yahoo.com/news/gilead-shot-prevents-100-hiv-140420191.html

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trials: First Zero Infections

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trials: First Zero Infections

Broke On: Thursday, 20 June 2024 Gilead's lenacapavir shows 100% efficacy and superiority in HIV prevention trials, marking the first Phase 3 study to demonstrate zero infections. The independent data monitoring committee recommended stopping the blinded phase and offering open-label lenacapavir to all participants due to its superiority over daily Truvada. This development brings Gilead closer to introducing a new form of PrEP and broadening its HIV business.